Andrew Sinclair left the role of Director at Adicet Bio, Inc., effective November 13, 2026. As of November 14, 2026, Adicet Bio, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on November 13, 2026, naming 1 departure (Form 8-K, November 13, 2026).
Adicet Bio, Inc. announced the departure of its Director on Nov 13. 29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Adicet Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Adicet Bio, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-11-13. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Adicet Bio, Inc. files it.
Also on the record for Adicet Bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 28, 2026 | Stake report, Schedule 13G/A, by Franklin Templeton, Inc. | 7.7% of the class | 5%+ stakes | Source |
| October 23, 2026 | Stake report, Schedule 13G, by Zedek Daniel Clayton | 5.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Woodline Partners LP | 3.3% of the class | 5%+ stakes | Source |
| April 13, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 12.3% of the class | 5%+ stakes | Source |
| April 10, 2026 | Stake report, Schedule 13D/A, by ORBIMED ADVISORS LLC | 8.8% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Woodline Partners LP | 6.5% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by TANG CAPITAL MANAGEMENT, LLC | 0.1% of the class | 5%+ stakes | Source |
| January 29, 2026 | Stake report, Schedule 13G, by Franklin Resources, Inc. | 6.5% of the class | 5%+ stakes | Source |
| October 10, 2025 | Stake report, Schedule 13D/A, by ORBIMED ADVISORS LLC | 9.6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Adicet Bio, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Adicet Bio, Inc. and the records around it.
Adicet Bio, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Watch Adicet Bio, Inc.
Get an email when Adicet Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Adicet Bio, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Adicet Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Adicet Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-13 | Out | Director | 2026-11-13 | 8-K, 2026-11-13 |
Why did they leave? What the filings say
For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Andrew Sinclair, Director (filed 2026-11-13):
Dr. Sinclair's resignation from the Board was not the result of any disagreement with management or the Board or on any matter relating to the Company's operations, policies or practices.
Who leads Adicet Bio, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Andrew Sinclair, departure reported, effective 2026-11-13 (filed 2026-11-13). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Adicet Bio, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Adicet Bio, Inc., with the record behind each one.
Find candidates like Director at Adicet Bio, Inc.Every change, in the filing's words
Departing: Andrew Sinclair, Director, effective 2026-11-13
On November 11, 2026, Andrew Sinclair, Ph.D., a Class III member of the board of directors (the "Board") of Adicet Bio, Inc. (the "Company"), notified the Company of his resignation from the Board, the Audit Committee of the Board (the "Audit Committee") and the Nominating and Corporate Governance Committee of the Board (the "NCG Committee"), effective on November 13, 2026.
- Departure of Directors or Certain Officers; Election of Directors.
- Effective upon Dr. Sinclair's resignation, the size of the Board will be reduced from seven to six.
- On November 13, 2026, upon the recommendation of the NCG Committee of the Board, the Board appointed current director Michael Grissinger to serve on the Audit Committee.
- The Board determined that Mr. Grissinger meets the requirements for independence of audit committee members under the listing standards of The Nasdaq Stock Market and the Securities and Exchange Act of 1934, as amended.
- Mr. Grissinger was also appointed to serve as chairperson of the NCG Committee.
Tools for this story
Each opens in a new tab, filled in for Adicet Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
